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Variable V1/V2 and V3 loops on human immunodeficiency virus type 1 (HIV-1) envelope-
gp120 core play key roles in modulating viral competence to recognize two infection
receptors, CD4 and chemokine-receptors. However, molecular bases for the modulation
largely remain unclear. To address these issues, we constructed structural models for
a full-length gp120 in CD4-free and -bound states. The models showed topologies
of gp120 surface loop that agree with those in reported structural data. Molecular
dynamics simulation showed that in the unliganded state, V1/V2 loop settled into a
thermodynamically stable arrangement near V3 loop for conformational masking of
V3 tip, a potent neutralization epitope. In the CD4-bound state, however, V1/V2 loop
was rearranged near the bound CD4 to support CD4 binding. In parallel, cell-based
adaptation in the absence of anti-viral antibody pressures led to the identification of
amino acid substitutions that individually enhance viral entry and growth efficiencies in
association with reduced sensitivity to CCR5 antagonist TAK-779. Notably, all these
substitutions were positioned on the receptors binding surfaces in V1/V2 or V3 loop.
In silico structural studies predicted some physical changes of gp120 by substitutions
with alterations in viral replication phenotypes. These data suggest that V1/V2 loop is
critical for creating a gp120 structure that masks co-receptor binding site compatible
with maintenance of viral infectivity, and for tuning a functional balance of gp120
between immune escape ability and infectivity to optimize HIV-1 replication fitness.
Keywords: homology modeling, MD simulation, V1/V2 loop, V3 loop, adaptive mutation
INTRODUCTION
An envelope glycoprotein (Env) of human immunodeﬁciency virus type 1 (HIV-1) is synthesized
in cells as a precursor gp160, and subsequently cleaved to mature gp120 and gp41. HIV-1 Env
works, as a trimer of a gp120-gp41 dimer molecule, on viral entry into target host cells (Freed and
Martin, 1995, 2013; Clapham andMcKnight, 2002;Wilen et al., 2012). Env-gp120 binds to receptor
CD4 and co-receptor CCR5 or CXCR4, whereas Env-gp41 mediates virus-cell membrane fusion.
Depending on the co-receptor usage,HIV-1 strains are grouped into CCR5 (R5)-tropic and CXCR4
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(X4)-tropic viruses. During the entry process, viral Env proteins
undergo large conformational changes. CD4 induces gp120
conformational change upon their binding, and facilitates
subsequent interaction with the co-receptor. Binding of gp120 to
the receptor and co-receptor triggers a drastic structural change
of gp41, and allows virus-cell membrane fusion. Successful entry
is crucial for establishing HIV-1 infection.
HIV-1 Env displays high adaptive capacity. This ability
enables HIV-1 to escape from host immune recognition with
maintenance of function/structure of Env involved in viral entry.
Consequently, HIV-1 Env exhibits an extensive genetic variation.
Based on genetic variations, gp120 consists of discontinuous ﬁve
conserved regions (C1 to C5) and ﬁve variable regions (V1 to
V5; Freed and Martin, 1995). Numerous studies have detailed
the role of each region in Env functions. V1/V2 and V3 form
ﬂexible loop structures on the gp120 core region (Huang et al.,
2005; McLellan et al., 2011) and have been shown to be involved
in modulation of the co-receptor usage, cell tropism, replication
ability and/or neutralization resistance (Freed and Martin, 1995,
2013; Clapham and McKnight, 2002; Tilton and Doms, 2010;
Benjelloun et al., 2012; Wilen et al., 2012; Connell and Lortat-
Jacob, 2013; Mascola and Haynes, 2013). Recent crystal and
cryo-electron microscopy (cryo-EM) structure studies on Env
have revealed that V1/V2 loops are located at the trimer apex in
connection with V3 loop, and that the conformational change of
V1/V2 loops upon CD4 binding triggers exposure of V3 loop to
the co-receptor (Julien et al., 2013; Lyumkis et al., 2013). These
results are the indicative of concerted action of V1/V2 and V3
loops during HIV-1 entry and thereby adaptation processes. In
this regard, we previously identiﬁed adaptive mutations in HIV-
1 Env-gp120 that are responsible for viral growth enhancement
in growth-restrictive cells of an R5-tropic and macaque/human
tropic HIV-1 derivative, NL-DT562 (562; Nomaguchi et al.,
2008, 2013a; Yamashita et al., 2008). These single-amino acid
substitutions were found to be clustered within V1/V2 and V3
domains (Nomaguchi et al., 2013a).
Critical issues that remain to be solved for better
understanding o f HIV-1 entry and adaptation can be
summarized as follows: (1) amino acid residue(s) essential
for the Env function are less well-deﬁned; (2) adaptive
mutation(s) that augment viral entry eﬃciency/replication
ability are not yet amply described; (3) how the adaptive
mutations alter viral phenotypes remain unclear. Although
atomic-level information on the natural gp120 structure is
essential to clarify each of these issues, such information is
still technically hard to obtain. While the small-angle x-ray
scattering (SAXS; Guttman et al., 2012) and cryo-EM (Lyumkis
et al., 2013) have provided invaluable information on the global
fold and shape of gp120 trimer on the virion, these techniques
are in principle unable to give the atomic-level information
on the protein structure. Meanwhile, the crystal structure
analysis is beneﬁcial to obtain the atomic-level information,
but most studies have focused on the gp120 core region and
are lacking in the ﬂexible loop regions. To date, only a few
studies have reported crystal structures of the full-length HIV-1
gp120 trimer (Julien et al., 2013; Pancera et al., 2014; Do
Kwon et al., 2015). In those studies, protein preparations for
crystallization were bound to anti-gp120 neutralizing antibodies,
and/or contained multiple mutations at V3 base/C5 regions
for structure stabilization and/or antigenicity modiﬁcation.
These physical modiﬁcations might inﬂuence structure and
function of native gp120. Thus, information on the full-length
gp120 structures obtained by distinct approaches would be
informative to complement available structural data of the
HIV-1 gp120.
In this study, we combined computational and experimental
approaches to gain new insights into the roles of gp120
variable loops in HIV-1 entry and their adaptive mutations.
By coupling homology modeling and molecular dynamics
(MD) simulation, we constructed R5-tropic full-length gp120
models that disclose key structural features to understand gp120
functions: topologies of the variable loops (Guttman et al.,
2012; Julien et al., 2013; Lyumkis et al., 2013; Pancera et al.,
2014; Do Kwon et al., 2015), conformational masking of V3
tip (Guttman et al., 2012; Munro et al., 2014; Pancera et al.,
2014), and CD4-induced conformational rearrangement (Huang
et al., 2005; Guttman et al., 2012; Julien et al., 2013; Pancera
et al., 2014; Do Kwon et al., 2015). Using the models and
MD simulation, we obtained evidence that V1/V2 loop is
critical to create gp120 structure that makes the masking of
co-receptor binding site for immune escape compatible with
the maintenance of viral infectivity. In parallel, cell-based viral
adaptation experiments in the absence of antibodies led to the
identiﬁcation of single amino acid substitutions in Env gp120
for better viral entry and replication. Structural models predicted
that these mutations resided in the receptors binding surface
and could modulate gp120 structures for receptors binding.
Our structural and virological data illustrate a previously less
characterized physical function of V1/V2, i.e., the regulation
of V3 conformation, for tuning viral infectivity and immune
escape ability to optimize viral replication ﬁtness in given
environments.
MATERIALS AND METHODS
Molecular Modeling of a Full-Length
gp120 Monomer in CD4-Free and -Bound
States
Three-dimensional (3-D) models for a full-length gp120
monomer of HIV-1 R5-tropic virus in CD4-free and -bound
states were constructed by assemblingmissing parts of the protein
surface onto the gp120 core of JRFL virus (GenBank accession
no. U63632), followed by homology modeling. Comparison of
gp120 core structures in public database indicated that overall
conformations of the cores were similar in the CD4-free and -
bound states except for V1/V2 stem region. Therefore, we used
the core structure with gp41-interactive region of HIV-1 JRFL
at a 2.61 Å resolution (PDB code:3JWD; Pancera et al., 2010)
as a common platform to construct full-length gp120 models.
Because 3JWD represents the core bound to soluble CD4, we
replaced its V1/V2 stem region with that of the CD4-free partial
core structure (PDB code: 3IDX, a 2.5 Å resolution; Chen et al.,
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2009) for modeling of gp120 in the CD4-free state. Other parts
of gp120 were same for the present modeling. To supplement
missing surface structures of gp120, we used partial structures as
follows: V1/V2 (PDB code: 3U4E, a 2.19 Å resolution; McLellan
et al., 2011), V3 (PDB code: 2QAD, a 3.3 Å resolution; Huang
et al., 2007), V4 (PDB code: 2B4C, a 3.3 Å resolution; Huang et al.,
2005), and C5 (PDB code: 1MEQ, solution nuclear magnetic
resonance structure; Guilhaudis et al., 2002). The gp120 core and
surface structures were used as templates to construct full-length
models for JRFL gp120 by homology modeling using ‘MOE-
Align,’ a tool for multiple sequence and structure alignment
for examining their relatedness1, and ‘MOE-Homology,’ a tool
to predict structure by the sequence and structure relatedness
in the Molecular Operating Environment MOE (Chemical
Computing Group Inc.). Obtained models were optimized by
energy minimization using MOE and an Amber10: Extended
Huckel Theory (EHT) force ﬁeld implemented in MOE, which
combines Amber10 and EHT bonded parameters for the large-
scale energy minimization (Gerber and Muller, 1995; Case et al.,
2005).
MD Simulation of a Full-Length,
Glycosylated gp120 in a CD4-Free State
A full-length, glycosylated gp120 model in a CD4-free state
was subjected to MD simulation essentially as described for
simulations of HIV-1/SIV gp120 outer domains (Naganawa et al.,
2008; Yokoyama et al., 2012; Kuwata et al., 2013; Yuan et al.,
2013). Brieﬂy, a high-mannose oligosaccharide Man5GlcNAc2
was added to potential N-glycosylation sites in gp120 outer
domains using Online Glycoprotein Builder2. MD simulations
were performed by the PMEMD (Particle Mesh Ewald Molecular
Dynamics) module in the AMBER 10 program package (Case
et al., 2005), employing the AMBER ﬀ99SB-ILDN force ﬁeld, a
protein force ﬁeld with improved side-chain torsion potentials
(Lindorﬀ-Larsen et al., 2010), the GLYCAM06 force ﬁeld, a
biomolecular force ﬁeld for glycans (Kirschner et al., 2008), and
the TIP3P water model for simulations of aqueous solutions
(Jorgensen et al., 1983). Bond lengths involving hydrogen were
constrained with SHAKE, a constraint algorithm to satisfy a
Newtonian motion (Ryckaert et al., 1977), and the time step for
all MD simulations was set to 2 fs. A non-bonded cutoﬀ of 10 Å
was used. After heating calculations for 20 ps until 310 K using
the NVT ensemble for the constant volume, temperature, and
numbers of particles in the system, simulations were executed
using the NPT ensemble for the constant pressure, temperature,
and numbers of particles in the system at 1 atm, at 310 K, and in
150 mMNaCl for 50 ns.
Molecular Modeling of HIV-1 gp120
Trimers in CD4-Free and -Bound States
For modeling of CD4-free trimer, the CD4-free monomer model
was superposed on the gp120 trimer structure derived from
the x-ray crystal structure of Env proteins (PDB code: 4TVP;
1https://www.chemcomp.com/journal/align.htm
2http://glycam.org/
Pancera et al., 2014). For modeling of CD4-bound trimer, the
CD4-bound monomer model was superposed on the gp120
trimer structural image derived from cryo-EM analysis of Env
proteins on the virion (PDB code: 3DNO; Liu et al., 2008).
Superimpositions of monomer structures were done using the
Protein Superpose module in MOE.
Prediction of the Effects of Amino Acid
Substitutions on the Stability and Affinity
of gp120-CD4 Complex
The 3-D model of HIV-1 562 full-length gp120 bound to
cynomolgus monkey CD4 (GenBank accession no. D63349) was
constructed by homology modeling usingMOE-Align andMOE-
Homology, and reﬁned by energy minimization and by the
Ramachandran plot using MOE. The full-length gp120 model in
a human soluble-CD4 bound state was used as a template for
homology modeling. The 562 gp120 and cynomolgus monkey
CD4 complex was used for in silico mutagenesis as described in
the study of HIV-1 capsid protein (Nomaguchi et al., 2013b).
Changes in the stability and aﬃnity of the gp120-CD4 complex
by mutations were computed by using the Protein Design
application in MOE, a computational tool for the structure
analysis of mutant proteins and for the computational design of
protein with desirable properties. Brieﬂy, single-point mutations
on the gp120 protein were generated, and ensembles of protein
conformations were generated by the LowMode MD module in
MOE, a tool of low-mode velocity ﬁltering for conformational
search, to calculate average stability and aﬃnity using Boltzmann
distribution. Finally, stability and aﬃnity scores of the structures
reﬁned by energy minimization were obtained through the
scoring function of the Protein Design application.
MD Simulation of gp120 V3 Loops
Molecular models for V3 loops of 562 and 562 S304G gp120
proteins were constructed by homology modeling using the
x-ray crystal structure of gp120 with V3 loop at a 3.30 Å
resolution (PDB code: 2QAD; Huang et al., 2007) as a modeling
template. The models represent V3 loop structures of gp120 in
the CD4-bound state, because the template gp120 was bound to
soluble CD4. The initial V3 models were thermodynamically and
physicochemically reﬁned using MOE. MD simulations of V3
loops were done essentially with the same calculation conditions
as described above for MD simulations of the full-length gp120.
After heating calculations for 20 ps until 310 K using the NVT
ensemble, simulations were executed using the NPT ensemble at
1 atm and at 310 K for 20 ns. Superimpositions of V3 structures
were done using the Protein Superpose module in MOE by
coordinating atoms of amino acid residues at V3 base.
Calculation of Root Mean Square
Deviation (RMSD) and Root Mean Square
Fluctuation (RMSF) Values
Root Mean Square Deviation and RMSF values were calculated
as previously described to quantify structural dynamics of
molecules in the MD simulations (Yokoyama et al., 2012). RMSD
values between the heavy atoms of the two superposed proteins
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were used to measure overall structural diﬀerences between the
two proteins (Case et al., 2005). We also calculated RMSF values
of the Cα atoms to obtain information on atomic ﬂuctuations
of individual amino acid residues during MD simulations (Case
et al., 2005). The 10,000 snapshots obtained fromMD simulations
of 10–20 ns were used to calculate RMSF values. The average
structures during the last 10 ns of MD simulations were used
as reference structures for RMSF calculation. Both RMSD and
RMSF values, which quantify the diﬀerences between the average
values and those obtained at give times of MD simulations, were
calculated using the ptraj module in Amber, a trajectory analysis
tool (Case et al., 2005).
Plasmid DNA
Construction and characterization of various proviral clones
designated pNL-DT562, pNL-DT5R, pNL4-3, and pNL-Kp
(NL4-3Env construct) were previously described (Adachi et al.,
1986, 1991; Kamada et al., 2006; Yamashita et al., 2008). Growth-
enhancing mutations were site-speciﬁcally introduced into pNL-
DT562 by using the QuickChange site-directed mutagenesis kit
(Agilent Technologies) as fully described previously (Nomaguchi
et al., 2013a, 2014).
Cells
A human monolayer cell line 293T (Lebkowski et al., 1985)
and a cynomolgus macaque lymphocyte cell line HSC-F (Akari
et al., 1999) were routinely maintained in Eagle’s MEM
supplemented with 10% heat-inactivated fetal bovine serum
and in RPMI1640 containing 10% heat-inactivated fetal bovine
serum, respectively.
Transfection, Reverse Transcriptase (RT)
Assay, and Infection
Virus samples were prepared from 293T cells transfected
with various proviral clones by the calcium-phosphate co-
precipitation method as previously described (Adachi et al.,
1986; Kamada et al., 2006; Nomaguchi et al., 2013a,b, 2014).
Virion-associated RT activity was measured to determine virus
amounts as described previously (Willey et al., 1988; Nomaguchi
et al., 2013b). For determination of viral growth kinetics, equal
amounts (RT units) of virus preparations were inoculated into
HSC-F cells, and infected cells were cultured in the presence of
IL-2 (50 U/ml). Virus replication was monitored every 3 days by
RT activity in the culture supernatants.
Entry Assay
Input virus samples for entry assays were prepared from
transfected 293T cells as above, and quantiﬁed by the HIV-
1 p24 antigen enzyme-linked immunosorbent assay (ELISA)
kit (ZeptoMetrix Corporation). Entry assays were performed as
previously described (von Schwedler et al., 1993; Adachi et al.,
1996). Brieﬂy, HSC-F cells (106) were incubated with viruses
(100 ng of p24) for 2 h at 4◦C, extensively washed, and collected
as viral binding fractions. To determine virus entry level, HSC-
F cells treated with viruses at 4◦C as above were trypsinized for
5 min at 37◦C, extensively washed, and incubated for 2 h at 37◦C
for preparation of viral entry fractions. The binding and entry
fractions were lysed, and the p24 level of samples was determined
by the ELISA kit as above. Entry eﬃciency of each sample was
calculated as p24 level of entry fraction/p24 level of binding
fraction. NL4-3 and NL-Kp (NL4-3Env) were used as positive
and negative controls, respectively.
Inhibitor Sensitivity Assays
To determine the co-receptor usage, HSC-F cells (105) were
treated with/without 1 μM co-receptor antagonists (CXCR4
antagonist AMD3100 and CCR5 antagonist TAK-779) at 37◦C
for 1 h, and equal virus amounts (105 RT units) were inoculated
into the pretreated cells. Co-receptor antagonists were present
in the cultures throughout the experiment. Virus replication was
monitored by RT activity released into the culture supernatants.
Viral yields in test cultures relative to those on the peak day
in cultures without antagonists were calculated. X4-tropic HIV-
1 derivative 5R served as a control. To determine sensitivity of
562 and its gp120-mutants to TAK-779, HSC-F cells (105) were
treated with serial 10-fold dilutions of TAK-779 (1–10−5 μM ) at
37◦C for 1 h, and viruses (106 RT units for 562 and 105 RT units
for gp120-mutants) were then inoculated into the pretreated
cells. TAK-779 concentration was maintained in the cultures
throughout the experiment. Virus replication was monitored by
RT activity released into the culture supernatants. Viral yields in
test cultures relative to those on the peak day in cultures without
TAK-779 were calculated.
RESULTS
MD Simulation of a Full-Length,
Glycosylated gp120 Protein Predicts a
Thermodynamically Stable Arrangement
of V1/V2 and V3 Loops in the CD4-Free
State
Because full-length gp120 structures of the same strain in CD4-
free and -bound states were unavailable at atomic levels in the
public database, we constructed them with the aid of in silico
science (see Materials and Methods for details of modeling).
Unliganded gp120 protein of HIV-1 is characterized to exist as
semi-stable state, i.e., local minimum of energy state, through
interactions of variable loops on the core surface (Kwon et al.,
2012). Maintaining such unique conformation is considered
to be critical for generating its functions in virus entry into
target cells and in immune/drug escape (Kwon et al., 2012).
To identify the functional arrangement of the variable loops at
semi-stable state of unliganded gp120 protein, we performed
MD simulation for the CD4-free gp120 model (Figure 1A).
To mimic physical properties of the native gp120, we added
high-mannose oligosaccharide Man5GlcNAc2 at the potential
N-glycosylation sites in gp120 outer domains of the initial model
before MD simulation. RMSD between the initial structure and
structures at given times of simulation sharply increased in the
beginning and reached a near plateau after 20 ns of the MD
simulations (Figure 1B). These results suggest that the structural
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FIGURE 1 | Continued
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FIGURE 1 | Continued
Molecular dynamics (MD) simulation of a full-length, glycosylated HIV-1JRFL gp120 monomer. (A) Schematic representation of molecular modeling and MD
simulation. Molecular model for a full-length, glycosylated gp120 monomer of HIV-1 R5-tropic virus JRFL in a CD4-free state was constructed by assembling of
HIV-1 gp120 parts and homology modeling. PDB codes of the structures used for modeling are indicated on the left. Thermodynamically and physically refined
model was subjected to MD simulation using the PMEMD module in the AMBER 10 program package as described for simulations of HIV-1/SIV gp120 outer
domains (Naganawa et al., 2008; Yokoyama et al., 2012; Kuwata et al., 2013; Yuan et al., 2013). (B) Time course of RMSD between the initial model and models at
given times of MD simulation. RMSD values were calculated with trajectories at every 2 fs of MD simulation using the ptraj module in Amber 10. (C) Time course of
distances between residues in V2 and V3 (red line), residues in V2 and β20-β21 (green line), and residues in V3 and β20-β21 (blue line) in gp120. (D) Structures of a
full-length, glycosylated gp120 monomer at 20, 30, 40, and 50 ns of MD simulations. V1/V2 and V3 regions are highlighted by red and blue colors, respectively.
(E) Distances between the variable loops and core. The distances between the Cα of P117 at core neighboring V1 base and Cα of G307 at the tip of V3 loop
(D117−307), Cα of L121 at core neighboring V1 base and the Cα of R163 at V2 loop (D121−163), and Cα of L172 at V2 loop and the Cα of Q324 at V3 base
(D172−324) were calculated with the gp120 model at 50 ns simulation and x-ray crystal structure (4TVP) to quantitatively compare relative 3-D locations of the V1/V2
and V3 loops on the core. Amino acid numbers are based on those of the JRFL Env protein (GenBank accession no. U63632).
distortions were relieved shortly after the start of simulation
under thermodynamic driving forces in solution. The data also
predict that the glycosylated gp120 structure can reach a state of
thermodynamic equilibrium in solution.
Of note, distances between V2 and V3, V2 and β20–β21,
and V3 and β20–β21 in gp120 reached a near plateau with low
levels of ﬂuctuations (Figure 1C). The data indicate that a stable
arrangement of V1/V2 and V3 on the glycosylated gp120 core
exists in solution in the CD4-free state. The data also suggest
that V1/V2 and V3 interactions conﬁne their free movements.
The results are consistent with a previous report on the physical
function of V1/V2 loop for the regulation of gp120 conformation
(Kwon et al., 2012). In this MD-predicted equilibrium state,
V1/V2 and V3 loops positioned at the opposite side from
the N- and C-terminal regions and continually ﬂuctuated over
time (Figures 1C,D). V1/V2 was extended from inner to outer
domains along core, whereas V3 was extended from outer to
inner domains along core (Figure 1D). The relative 3-D locations
of V1/V2 loop, V3 loop, and N/C termini on the core in the
equilibrium state agree with those reported in the structural
model constructed with SAXS data of a CD4-free full-length
gp120 (Guttman et al., 2012). The relative 3-D locations also
agree with those in the cryo-electron tomography reconstruction
model (Lyumkis et al., 2013) and the x-ray crystal structures
(Julien et al., 2013; Pancera et al., 2014; Do Kwon et al.,
2015) for gp140 containing whole gp120 and the ectodomain
of gp41. To quantitatively address this issue, we measured the
distances between the variable loops and core at three sites
(D117−307, D121−163, and D172−324) using our gp120 model at
50 ns simulation and x-ray crystal structure at pre-fusion state
(4TVP; Figure 1E). The diﬀerences in distances between the
model and x-ray crystal structure were 2.73, 1.81, and 2.32 Å for
the D117−307, D121−163, and D172−324, respectively, which were
within the range of resolution of the 4TVP (3.1 Å). Thus, the
gp120 structure model at 50 ns in the equilibrium state closely
recapitulates relative 3-D locations of V1/V2 and V3 loops on the
core of the x-ray crystal structure.
Conformational Masking of a
Co-Receptor Binding Site in the
Ligand-Free, Trimeric gp120
Env gp120 V3 loop element is critical for co-receptor binding
for HIV-1 entry into target cells and determines viral co-receptor
tropism (Hwang et al., 1991). The tip region of V3 loop therefore
constitutes a potent neutralization epitope (Goudsmit et al., 1988;
Palker et al., 1988; Rusche et al., 1988; Javaherian et al., 1989).
However, studies on viral neutralization (Bou-Habib et al., 1994;
Stamatatos and Cheng-Mayer, 1995; Krachmarov et al., 2005;
Lusso et al., 2005), gp120 conformational dynamics (Munro et al.,
2014), and V3 sequence evolution (Sato et al., 1999; Shiino et al.,
2000) consistently indicate that this epitope is generally concealed
from the antibody access in the primary isolates. HIV-1 R5-
tropic virus clone JRFL used in the present modeling study is
also a neutralization-resistant tier-2 primary isolate from anHIV-
1 infected individual (Koyanagi et al., 1987). To assess whether
our model here predicts this conformational masking on virion,
we constructed a full-length gp120 trimer model by superposing
the structure at 50 ns of MD simulation on the x-ray crystal
structure of envelope gp140 trimer (PDB code: 4TVP; Figure 2).
Whereas V3 tip was exposed on the gp120 at the monomeric state
(Figure 2A), this region was positioned toward the center at the
trimeric state so that V3 tip is sterically concealed (Figure 2B).
These results are consistent with those in the SAXS-based gp120
model (Guttman et al., 2012), the x-ray crystal structure of
gp140 (Pancera et al., 2014), and the single-molecule ﬂuorescence
resonance energy transfer imaging (Munro et al., 2014).
Conformational Rearrangement of V1/V2
and V3 Loops After CD4 Binding
Virological (Moore et al., 1992; Lee et al., 1997) and structural
(Huang et al., 2005; Julien et al., 2013; Lyumkis et al., 2013;
Pancera et al., 2014; Do Kwon et al., 2015) studies consistently
suggest that following CD4 binding, the gp120 surface undergoes
conformational changes from co-receptor-binding-incompetent
to -competent form. To address this issue, we constructed a
full-length gp120 model in a CD4-bound state (Figure 3A).
The global shape and structural topologies of variable loops
of this model are consistent with those in the SAXS-based
gp120 model in the CD4-bound state (Guttman et al., 2012).
Comparison of our gp120 models in the CD4-free (Figure 2A)
and -bound (Figure 3A) states shows that the core structures of
the two models are similar except for the secondary structure of
V1/V2 stem. This diﬀerence, however, caused marked diﬀerence
in arrangements of V1/V2 and V3 loops on the core. In the
CD4-free state, V1/V2 was positioned near V3 loop so that the
variable surfaces could interact with each other to maintain a
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FIGURE 2 | Model for a full-length HIV-1JRFL gp120 in a CD4-free state. (A) Full-length gp120 monomer model. The structure at 50 ns of MD simulation in
Figure 1D is shown. Glycans are removed for clear view of the outer domain. A red asterisk indicates the location of CD4-binding loop. (B) Full-length gp120 trimer
model. The model was constructed by superposing CD4-free monomer model on the x-ray crystal structure of Env gp140 protein (PDB code: 4TVP; Pancera et al.,
2014). Side and top views are shown on the left and on the right, respectively. V1/V2 and V3 regions are highlighted by red and blue colors, respectively.
stable arrangement on the core (Figures 1B–D, and 2A). In
the CD4-bound state, however, V1/V2 loop is rearranged near
the bound CD4 to support CD4 binding: V1/V2 stem formed
bridging sheet in combination with β20–β21 loop so that V1/V2
loop could interact with CD4 instead of V3 (Figure 3A). This
V1/V2 repositioning is consistent with the SAXS-based gp120
model for the CD4-bound state (Guttman et al., 2012). Due to
this conformational rearrangement in the CD4-bound state, V3
loop became free from structural constraints imposed by the
V1/V2 interactions and protruded out of the core surface for co-
receptor interactions in the trimer state (Figure 3B). These results
agree with what was proposed previously for the conformational
rearrangements of gp120 variable surface upon CD4 binding
(Guttman et al., 2012).
Each Individual Adaptive Single-Amino
Acid Mutation in V1/V2 and V3 Regions
of 562 Env-gp120 Enhances Viral Growth
Potential
Our structural study suggests that V1/V2 region is critical
for determining viral phenotypes via regulating topology and
conformation of V3 loop. Considering that V1/V2 and V3 loop
are variable, we assumed that these regions might be critical for
adaptive mutations under changing environments.
To address this issue, we examined here how HIV-1 adapts
in our cell-based HIV-1 assay system (Kamada et al., 2006;
Nomaguchi et al., 2008, 2013a). While multiple selective
factors including the host immune response drive virus
adaptation/evolution in individuals, only those that aﬀect
viral replication ability itself contribute to virus adaptation
in the cell culture system, providing simple experimental
means to study HIV-1 adaptation for entry. Previously,
we performed continuous cultivation of 562 and its X4-
tropic version NL-DT5R (5R) under growth-restrictive
conditions imposed by macaque cell lines (Nomaguchi et al.,
2013a). In our repeated experiments, 562 and 5R frequently
acquired growth-enhancing adaptive mutations in both Pol-
integrase and Env-gp120 regions (Nomaguchi et al., 2013a,
2014).
In this study, we focused on analyzing the changes in
the 562 Env-gp120 to understand structural bases for growth
adaptation. Remarkably, the nine single-amino acid substitutions
frequently emerged during the adaptation experiments were
all positioned at V1/V2 or V3 domain (Nomaguchi et al.,
2013a; Figure 4A). Authentic amino acid residues at the
mutation sites are relatively well-conserved among HIV-1
strains, and represented the most dominant ones (Figure 4B).
Substituted amino acid residues by the adaptations were all
found in nature, but usually at much lower frequencies as
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FIGURE 3 | Model for a full-length HIV-1JRFL gp120 in a CD4-bound state. (A) Full-length gp120 monomer model. Molecular model for a soluble CD4-bound
full-length gp120 monomer was constructed as described in section “Materials and Methods.” (B) Full-length gp120 trimer model. The model was constructed by
superposing CD4-bound monomer model on the Env structure derived from cryo-EM analysis (PDB code: 3DNO; Liu et al., 2008). Side and top views are shown on
the left and on the right, respectively. V1/V2 and V3 regions are highlighted by red and blue colors, respectively.
compared with the authentic ones (Figure 4B). These data
suggest that the nine sites are intrinsically variable in nature,
yet receive constraints on changes under standard replication
and transmission conditions. To address biological impacts
of these single substitutions, we comparatively analyzed the
growth-potentials of a parental clone 562 and its mutants
carrying each amino acid substitution. Seven substitutions,
L124F, N132K, G150R, F174L, S304G, I307V, and G310R,
markedly enhanced replication ability relative to that of 562
(Figure 5A). Furthermore, these mutations except for G310R
similarly promoted viral growth in human cells (data not
shown). The eﬀect of P181T and G308E substitutions on
viral growth was modest (Figure 5B), and therefore, these
substitutions were not included in the subsequent analyses.
To examine whether a combination of substitutions has an
additive enhancing eﬀect, we constructed proviral double mutant
clones containing various combinations of substitutions, and
compared their replication abilities with those of parental
562 and single mutant viruses (Figure 5C). Although viruses
carrying combined substitutions in V1/V2 and V3 grew more
eﬃciently than 562, additive enhancing eﬀects resulted from these
double substitutions and a double V3 substitution (S304G and
I307V) were not observed. Similar results were obtained for the
other double substitutions of V1/V2 and V3 loops (data not
shown).
Adaptive Mutations in 562 Env-gp120
Contribute to Increase in Entry Efficiency
via the Enhancement of Affinity for CCR5
Next, we examined the eﬀect of these substitutions on viral
entry eﬃciency. Virus samples were prepared from 293T
cells transfected with proviral constructs (562 and 562
mutants carrying each growth-enhancing substitution).
Entry assays in HSC-F cells were then performed in a
two-step reaction: virus binding step in which virus-cell
mixtures were kept at 4◦C; subsequent virus penetration
step in which cells after virus binding were incubated at
37◦C. Entry eﬃciency of each virus sample was calculated
as p24 level of penetrated virus into cells relative to
that of attached virus onto cells. Notably, all the seven
substitutions enhanced the viral entry eﬃciency in cells
(Figure 6A). These data suggest that adaptive mutations in
562 Env-gp120 promote viral replication by increasing entry
eﬃciency.
Since it has been shown that alterations in V1/V2 and V3
regions modulate the co-receptor usage (Freed and Martin,
1995, 2013; Clapham and McKnight, 2002; Tilton and Doms,
2010; Benjelloun et al., 2012; Wilen et al., 2012; Connell and
Lortat-Jacob, 2013; Mascola and Haynes, 2013), we determined
the susceptibility of above mutants to co-receptor antagonists.
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FIGURE 4 | Continued
Genetic information on HIV-1 gp120 adaptive mutations in the present study. (A) Location of HIV-1 adaptive mutations in Env-gp120. Amino acid sequences
in V1 to V3 regions of HIV-1 R5-tropic 562 virus (Nomaguchi et al., 2013a) carrying the SF162 env gene (GenBank accession no. EU123924; Kawamura et al., 1994)
are aligned with those of R5-tropic JRFL clone (GenBank accession no. U63632) and of X4-tropic HXB2 clone (GenBank accession no. K03455). Assignment of V1,
V2, and V3 regions is based on gp120 structure: V1/V2 (PDB code: 3U4E), V3 (PDB code: 2QAD). (B) Frequency of authentic (light blue) and replaced (red) amino
acid residues. Others (green) represent amino acid residues other than authentic and replaced ones. Naturally occurring amino acid residues at specific positions,
where adaptive 562-gp120 mutations are located, were investigated in an HIV-1 subtype B population from different geographic regions in the world (19,419
sequences), and are graphically shown. The 19,419 sequences were obtained from the HIV Sequence Database (http://www.hiv.lanl.gov/content/sequence/HIV/
mainpage.html).
FIGURE 5 | Growth properties of 562 derivative viruses carrying various adaptive mutations in gp120. (A) Growth kinetics of variant viruses carrying a
single adaptive mutation. Virus samples were prepared from 293T cells transfected with indicated proviral clones, and inoculated into HSC-F cells. Virus replication
was monitored by RT activity released into the culture supernatants. Data of left and right panels were obtained from the same experiment, and the same result for
562 is separately shown as a control. Infection condition: 2 × 105 RT units/2 × 105 cells. (B) Growth properties of slowly growing variant viruses carrying a single
adaptive mutation. Experiment was performed as described above. Infection condition: 4 × 106 RT units/106 cells. (C) Growth kinetics of variant viruses carrying
two adaptive mutations. Experiments were performed as above. LF, L124F; NK, N132K; GR, G150R; FL, F174L; SG, S304G; IV, I307V; GR, G310R. Infection
conditions: left, 2 × 105 RT units/2 × 105 cells; right, 5 × 104 RT units/1 × 105 cells.
Virus samples were prepared from 293T cells transfected with
proviral constructs (5R, 562 and 562 mutants carrying each
growth-enhancing substitution), and inoculated into HSC-F cells
pretreated with the antagonists. As is clear in Figure 6B, the
replication of 5R was inhibited in the presence of AMD3100
(anti-CXCR4), but not TAK-779 (anti-CCR5). Conversely,
the replication of 562 and its single-amino acid mutants
(L124F, N132K, G150R, F174L, S304G, I307V, and G310R)
was restricted in the presence of TAK-779, but not AMD3100
(Figure 6B). These results indicate that the viral co-receptor
tropism is not aﬀected at all by the above mutations in
Env-gp120.
It has been demonstrated that the Env with enhanced
aﬃnity for co-receptor displays increased resistance to entry
inhibitors (e.g., T-20) and co-receptor antagonists (e.g., TAK-
779; Reeves et al., 2002; Lobritz et al., 2007; Pacheco et al.,
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FIGURE 6 | Continued
Effects of growth-enhancing mutations in gp120 on viral entry. (A) Entry efficiency into HSC-F cells of 562 and 562 carrying indicated single substitutions.
Virus samples were prepared as in Figure 5, and entry assays were performed as described in section “Materials and Methods.” Values obtained for Env construct
(NL-Kp) were subtracted from those for test samples. Entry efficiency of each virus relative to that of 562 is presented. (B) Co-receptor usage of various viruses.
Infection of HSC-F cells with viruses was performed as described above, and infected cells were cultured in the absence or presence (1 μM) of antagonists (CXCR4
antagonist AMD3100 or CCR5 antagonist TAK-779). Virus replication was monitored by RT activity released into the culture supernatants. Viral yields in test cultures
relative to those on the peak day in cultures without antagonists were determined. 5R and 562 served as controls. (C) Sensitivity of 562 and its mutants to TAK-779.
Virus samples prepared as above were inoculated into HSC-F cells pretreated with the indicated concentration of TAK-779. Virus replication was monitored by RT
activity released into the culture supernatants. Viral yields in test cultures relative to those on the peak day in cultures without TAK-779 were determined and
presented as % inhibition. Representative results from three independent experiments are shown.
2008). Therefore, we compared the sensitivity of 562 and its
mutants to TAK-779 (Figure 6C). HSC-F cells pretreated with
increasing concentrations of TAK-779 were infected with 562
or its mutants (L124F, N132K, G150R, F174L, S304G, I307V,
or G310R). A high concentration of TAK-779 was required to
completely restrict the replication of viral clones containing
mutations L124F/N132K/G150R/F174L/S304G/I307V, and a
mutant clone carrying G310R was modestly more resistant to
TAK-779 relative to 562. These results show that the growth-
enhancing mutations in 562 Env-gp120 clearly enhance,
without exception, the aﬃnity for CCR5. Collectively,
the results obtained show that adaptive mutations in
562 Env-gp120 promote viral replication by enhancing
entry eﬃciency through increase in the aﬃnity for
CCR5.
Three-D Locations and Structural
Impacts of the Adaptive Mutations
In parallel with the above experimental study, we investigated
3-D locations and possible structural impacts of the adaptive
mutations to gain insights into how the mutations change the
viral phenotype. Interestingly, whereas the seven substitutions
were sporadically distributed along the gp120 core surface before
CD4 binding (Figure 7A), all of them were rearranged at
or near the potential sites for CD4 or co-receptor binding
after CD4 binding (Figure 7B): they were positioned either
around the CD4 binding surface in the V1/V2 region or at
the V3 tip/stem region. The data suggest that some of these
mutations may inﬂuence the gp120 structure for receptors
binding.
To address the inﬂuence on gp120 binding to CD4, we
constructed a 3-D model of 562 full-length gp120 bound to
cynomolgus monkey CD4 (GenBank accession no. D63349),
and performed in silico mutagenesis as described in the
study of HIV-1 capsid protein (Nomaguchi et al., 2013b).
Four point mutations (N132K in V1/F174L in V2/S304G
in V3/I307V in V3) were predicted to reduce the stability
of gp120-CD4 complex, whereas the other three (L124F in
V1/G150R in V1/G310R in V3) were expected to increase
the stability (Figure 8A). Thus, some adaptive mutations were
assumed to be disadvantageous in terms of the stability of
CD4 bound structure. Nevertheless, they appeared reproducibly
during adaptation in macaque cells (Nomaguchi et al., 2013a),
indicating that some advantage(s) surpasses the harmful eﬀect.
Aﬃnity scores predicted that the point mutations L124F and
G150R in V1, which increase the stability of gp120-CD4
complex (Figure 8A), also increase the binding aﬃnity of gp120
and CD4 (Figure 8B). These results suggest that these V1
mutations can cause structural changes in gp120 to improve CD4
binding.
V3 loop conformation is critical for interactions with the
N-terminal portion of CCR5 (Huang et al., 2005, 2007), and
amino acid substitutions within V3 loop can inﬂuence its
conformational dynamics, changing the viral co-receptor tropism
and neutralization sensitivity (Naganawa et al., 2008; Yokoyama
et al., 2012; Kuwata et al., 2013). We therefore examined
whether V3 adaptive substitutions aﬀect the conformational
dynamics of V3 loop using MD simulation (Figure 9).
We selected S304G substitution in this study, because the
substitution most reproducibly and frequently emerged in our
adaptation experiments (Nomaguchi et al., 2013a). Introduction
of S304G substitution into the V3 stem of 562 clone resulted
in enhancement of the RMSD ﬂuctuations (Figure 9A)
and in rearrangement of the V3 tip (Figure 9B). This
substitution exchanges serine with glycine, the smallest amino
acid residue, and rationally increased magnitudes of the V3
loop ﬂuctuation (Figure 9C), leading to reduced probability
to form a stable antiparallel β-sheet that contains 5–6 main-
chain hydrogen bonds (Figure 9D, left panel) and a turn at
base/stem region of V3 during the simulations (Figure 9D,
right panel). These data suggest that S304G substitution
can modulate structural features of V3 loop for co-receptor
interactions.
DISCUSSION
In this study, we combined computational and experimental
approaches to address how HIV-1 Env gp120 mechanically
modulates viral phenotypes and contributes to viral adaptation.
By coupling homology modeling and MD simulation, we
constructed full-length gp120 models that disclose key features
on the gp120 structure, i.e., topologies of the variable loops
(Guttman et al., 2012; Julien et al., 2013; Lyumkis et al., 2013;
Pancera et al., 2014; Do Kwon et al., 2015), conformational
masking of V3 tip (Guttman et al., 2012; Munro et al.,
2014; Pancera et al., 2014), and CD4-induced conformational
rearrangement (Huang et al., 2005; Guttman et al., 2012; Julien
et al., 2013; Pancera et al., 2014; Do Kwon et al., 2015;
Figures 1–3). In parallel, cell-based adaptation experiments
led to the identiﬁcation of single amino acid substitutions
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FIGURE 7 | The 3-D locations in a full-length gp120 of adaptive mutations. Adaptive amino acid substitutions are highlighted by colored globules on the
gp120 models in CD4-free (A) and CD4-bound (B) states. Amino acid residues in V1/V2 and V3 regions are highlighted by red and blue colors, respectively. For
details of the two models, see Figures 2A and 3A.
in Env gp120 for enhanced viral entry/growth through better
aﬃnity for CCR5 (Figures 4–6). Our structural models
predicted that these mutations resided on the receptor binding
surfaces and could modulate gp120 structures for receptors
binding (Figures 7–9). These ﬁndings suggest that amino
acid substitutions on the receptors binding surface are a key
mechanism to tune viral entry eﬃciency during HIV-1 growth
adaptation.
Most importantly, MD simulation of the full-length gp120
molecule revealed a physical function of V1/V2 loop. In the
CD4-free state, V1/V2 loop, which initially positioned away
from V3 loop, settled into a ﬁxed position near the V3 loop to
ﬁt in a thermodynamically stable arrangement (Figure 1). The
results suggest presence of semi-stable state, i.e., local minimum
of energy state for the full-length unliganded gp120. In this
semi-stable state, V1/V2 and V3 loops were stably arranged
near the core under mutually interactive compact positions
(Figures 1B–D). This stable arrangement of variable loops on
the core is reasonable from the viewpoint of protein chemistry,
because unliganded protein generally fold into a compact
conformation with minimum protein surface in solution. More
importantly, the relative 3-D locations of the variable loops
on the core surface in the semi-stable state agree with those
reported in the previous experimental studies (Guttman et al.,
2012; Julien et al., 2013; Lyumkis et al., 2013; Pancera et al., 2014;
Do Kwon et al., 2015) and explain the well-known experimental
observation, i.e., conformational masking of V3 neutralization
epitope in the trimeric context (Guttman et al., 2012; Munro
et al., 2014; Pancera et al., 2014) with keeping CD4 binding site
accessible (Figure 2). Thus, the present unliganded gp120 model
in the semi-stable state recapitulates structural and virological
features of the functional gp120 revealed by various experimental
methods. Our MD simulation study additionally suggests that
V1/V2 loop has an intrinsic physicochemical feature that attracts
V3 loop in the CD4-free state. These ﬁndings are well consistent
with a previous notion that in the CD4-free state, shift to CD4-
bound conformation is restrained by interactions of V1/V2 and
V3 loops (Kwon et al., 2012). In the CD4-bound state, however,
V1/V2 loop repositioned near the bound CD4 to support
CD4 binding, while V3 loop formed exposed conformation for
co-receptor binding via relief from V1/V2 loop (Figure 3).
Taken together, these results strongly suggest that V1/V2 loop
functions as a nano device to create a gp120 structure that masks
co-receptor binding site for immune evasion compatible with
maintenance of viral infectivity.
Present study also provides structural bases to understand how
V1/V2 and V3 loops mechanically modulate various biological
phenotypes of HIV-1. Ligand-free gp120 models (Figures 1 and
2) predict that changes in the physicochemical features of V1/V2
or V3 loop, by amino acid substitutions or glycosylation, would
alter the nature of attractive interactions among these loops in the
CD4-free state. Such changes in turn could cause changes in the
exposure levels of co-receptor binding site on virions and thereby
would alter viral neutralization sensitivity to anti-V3 antibodies
(Etemad-Moghadam et al., 1999; Pinter et al., 2004; Krachmarov
et al., 2006; Naganawa et al., 2008), as well as fusogenic activity
of gp120 and viral infectivity (Sullivan et al., 1993; Ogert et al.,
2001; Laird et al., 2008; Cavrois et al., 2014). In addition,
CD4-bound gp120 models (Figure 3), in silico mutagenesis of
gp120 (Figure 8), and MD simulation of V3 loop (Figure 9)
suggest that changes in the loops could alter the eﬃciency
of receptors binding in the CD4-bound state. For example,
L124F and G150R substitutions in V1 loop were predicted to
increase gp120 binding aﬃnity for CD4 (Figure 8), and S304G
substitution in V3 loop was expected to alter conformational
dynamics of V3 loop (Figure 9). Although structural impacts by
the adaptive mutations remained characterized further, present
ﬁndings suggest that a combination(s) of multiple rather than
Frontiers in Microbiology | www.frontiersin.org 13 February 2016 | Volume 7 | Article 110
Yokoyama et al. Structural Modeling of HIV-1 Env-gp120
FIGURE 8 | Effects of amino acid substitutions on the stability and affinity of gp120-CD4 complex. Full-length 562 gp120-CD4 complex model was
constructed as described in section “Materials and Methods,” and used for in silico mutagenesis (Nomaguchi et al., 2013b). Changes in the stability (A) and affinity
(B) scores by single amino acid substitutions were computed by using the Protein Design application in MOE as described in section “Materials and Methods.” Bars
indicate standard deviations of the score (n = 3).
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FIGURE 9 | Effects of S304G mutation on molecular dynamics of V3 loop. Molecular models for 562 and 562 S304G V3 loops were constructed by homology
modeling and subjected to MD simulations as described in section “Materials and Methods.” (A) Time course of RMSD between the initial model and models at
given times of MD simulation. (B) Superposition of V3 structures obtained during 10–20 ns of MD simulations. (C) Distribution of RMSF in V3 loop. RMSF values that
represent atomic fluctuations of the main chains of individual amino acids were calculated with 10,000 snapshots from 10 to 20 ns of each MD simulation.
(D) Distributions of frequencies of β-sheet and turn structures in V3 loop that were formed during MD simulations. RMSD, RMSF, and frequencies were calculated
using the ptraj module in Amber (Case et al., 2005). Red arrows in (B), (C), and (D) show the position of S304G mutation. Red and blue lines in (C) and
(D) represent data on 562 and 562 S304G clones, respectively.
a single mechanism, such as alterations in physical interactions
among V1/V2 and V3 loops in the unliganded state and/or
alterations in physical interactions with CD4/CCR5, governed
the modulation of growth phenotypes of Env-gp120 mutants in
this study.
Present study further provides structural insights into the
HIV-1 adaptation. Considering that V3 tip constitutes a potent
neutralization epitope (Goudsmit et al., 1988; Palker et al., 1988;
Rusche et al., 1988; Javaherian et al., 1989), HIV-1 needs to
keep evading swarms of newly generated anti-V3-tip antibodies
against replicating viruses during persistent infection in infected
individuals. A key evasion mechanism is considered to be
masking of the co-receptor binding site in V3 (Bou-Habib et al.,
1994; Stamatatos and Cheng-Mayer, 1995; Krachmarov et al.,
2005; Lusso et al., 2005), i.e., V3 tip. Meanwhile, persisting viruses
also should maintain their infectivity that requires the exposure
of the co-receptor binding site (Huang et al., 2005), i.e., V3 tip.
As suggested in the present study, V1/V2 loop seems to be an
essential device to create structural compatibility of gp120 for
these reciprocal requirements. Considering that V1/V2 and V3
loops are intrinsically highly variable (HIV Sequence Database3),
it is conceivable that conﬁgurations of V1/V2 andV3 loops would
also have variations in nature. The structural variations on the
gp120 surface generated by variable loops would in turn allow
natural selection of the ﬁttest viruses as suggested in previous
(Nomaguchi et al., 2013a) and present (Figures 5–9) studies on
the HIV-1 Env adaptation. Thus, our structural and virological
data are consistent with the assumption that variable V1/V2
and V3 loops are key devices to create structural variations of
the gp120 surface to optimize replication ﬁtness under given
environments.
The authentic amino acid residues, at the sites that acquired
adaptive mutations are located, are relatively well-conserved
among virus strains from all HIV-1 subtypes (Zolla-Pazner and
Cardozo, 2010; for subtype B, see Figure 4B). Interestingly,
both F(Phe)/L(Leu) at position 174 and both S(Ser)/G(Gly) at
position 304 exist as natural variants (Figure 4B). Mutation of
3http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html
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F174 residue has been shown to aﬀect binding of a V2-speciﬁc
antibody 697-D and of neutralizing antibodies PG9 and PG16
(Zolla-Pazner and Cardozo, 2010). It is intriguing to see how
the replication of viruses carrying F174L mutation is regulated
in individuals. Notably, a particular V3 mutation (S304G)
reproducibly appeared with high frequency in the long-term
cultures of 562-infected macaque cell lines, and enhanced viral
replication ability not only in macaque cells but also in human
cells (Nomaguchi et al., 2013a). Even for primary HIV-1 isolates
from infected patients, serine and glycine at this position coexist
within an individual patient in some cases (Troyer et al., 2005;
Delobel et al., 2007; Recordon-Pinson et al., 2013). These results
suggest that the S304G mutation is a very powerful mutation to
increase replication ﬁtness of R5-tropic HIV-1 virus in primate
cells. Nevertheless, this mutation has been reported to be minor
in an R5-tropic virus population in humans (serine, 88% and
glycine, 12%; Hung et al., 1999) and in SHIVSF162P3-infected
macaques (Harouse et al., 2001; Ho et al., 2007; Tasca et al., 2008).
These ﬁndings suggest the presence of some selective pressure(s)
that restrict overgrowth of the S304G variant in vivo. In this
regard, we previously reported that V3 mutation is very potent
in modulating ﬂuctuation and conformation of the interaction
surface of gp120 outer domain (Naganawa et al., 2008; Yokoyama
et al., 2012). Therefore, the S304G mutation may augment
eﬃciency of gp120 binding not only to co-receptors but also to
neutralization antibodies. Further study is necessary to address
this issue.
In summary, our in silico analysis revealed the impact of HIV-
1 Env-gp120 MD on viral replication. We show here structural
and virological evidences that V1/V2 and V3 loops of HIV-1 Env
gp120 function as key nano devices to create the Env structure
suitable for immune escape compatible with maintenance of viral
infectivity, or to acquire adaptive mutations for enhancing viral
replication ability. Interlinking in silico science with virology is a
powerful strategy for better understanding of HIV-1 adaptation
and its biological signiﬁcance.
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